TY  - GEN
AU  - Honglian,Ma
AU  - Zhouguang,Hui
AU  - Fang,Peng
AU  - Lujun,Zhao
AU  - Dongming,Li
AU  - Yujin,Xu
AU  - Yong,Bao
AU  - Liming,Xu
AU  - Yirui,Zhai
AU  - Xiao,Hu
AU  - Jin,Wang
AU  - Yue,Kong
AU  - Lvhua,Wang
AU  - Ming,Chen
TI  - Different administration routes of recombinant human endostatin combined with concurrent chemoradiotherapy might lead to different efficacy and safety profile in unresectable stage III non-small cell lung cancer: Updated follow-up results from two phase II trials
SN  - 1759-7714
PY  - 2021///0311
KW  - Adenocarcinoma of Lung
KW  - pathology
KW  - Administration, Intravenous
KW  - Carcinoma, Non-Small-Cell Lung
KW  - Carcinoma, Squamous Cell
KW  - Chemoradiotherapy
KW  - mortality
KW  - Endostatins
KW  - administration & dosage
KW  - Female
KW  - Follow-Up Studies
KW  - Humans
KW  - Lung Neoplasms
KW  - Male
KW  - Middle Aged
KW  - Patient Safety
KW  - Prognosis
KW  - Survival Rate
N1  - Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1111/1759-7714.13333
ER  -